<DOC>
	<DOCNO>NCT00514501</DOCNO>
	<brief_summary>This open-label phase 2 study recruit low , moderate , high likelihood ACS patient approximately 60 center . Patients image iodofiltic acid I 123 detection myocardial ischemia . Readers independent clinical study center review result image study blind fashion image core lab . The result independent reading image compare truth standard ACS .</brief_summary>
	<brief_title>Safety Efficacy Iodofiltic Acid I 123 Treatment Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Provide write informed consent willing comply protocol requirement Are 40 year age old . Are evaluate possible ACS . If female , childbearing potential documented history negative serum urine pregnancy test within 4 hour prior receive test drug agree use acceptable form birth control . &lt; 40 year age . Females pregnant lactating . History leave ventricular ejection fraction ( LVEF ) =40 % . History MI . Acute ST segment elevation ECG . Left bundle branch block ECG . Known history significant allergy xray contrast medium iodine/iodides . Currently formerly medication target fatty acid uptake metabolism , eg ranolazine , ( Ranexa ) . Administered radiopharmaceutical rubidium82 thallium201 within 2 day prior study enrollment . Underwent cardiac stress test kind within 2 day prior study enrollment . Serum creatinine level &gt; 2.0 mg per dL . Received investigational compound and/or medical device within 30 day admission study . Qwave abnormality consistent previous MI</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>